DiaMedica Therapeutics
DMAC
9 hedge funds and large institutions have $3M invested in DiaMedica Therapeutics in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
8.65% more ownership
Funds ownership: 0% → 8.65% (+8.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$1.49M |
| 2 |
GIPM
G2 Investment Partners Management
New York
|
+$691K |
| 3 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
+$628K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$408K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$18.5K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WC
1
Wexford Capital
West Palm Beach,
Florida
| $1.38M | +$1.49M | +475,000 | New |
|
|
GIPM
2
G2 Investment Partners Management
New York
| $640K | +$691K | +219,973 | New |
|
|
MHP
3
Manatuck Hill Partners
Westport,
Connecticut
| $582K | +$628K | +200,000 | New |
|
|
WVP
4
Worth Venture Partners
Fort Lee,
New Jersey
| $377K | +$408K | +129,863 | New |
|
|
5
Bank of America
Charlotte,
North Carolina
| $17K | +$18.5K | +5,900 | New |
|
6
UBS Group
Zurich,
Switzerland
| $4K | +$4.16K | +1,323 | New |
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$1.58K | +503 | New |
|
8
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$141 | +45 | New |
|
|
GCM
9
Gables Capital Management
Miami,
Florida
| – | +$393 | +125 | New |
|
DMAC Hedge Fund Activity: Q4 2018 in Review
9 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2018, worth a combined $3M.
Buyers outnumbered sellers: 9 funds opened new DMAC positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wexford Capital, opening a new position worth an estimated $1.49M.
- 9 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $3M of DiaMedica Therapeutics stock for Q4 2018.
- 9 funds opened new DiaMedica Therapeutics positions in Q4 2018 and 0 closed out, a net change of +9 holders.
- The largest DiaMedica Therapeutics buyer in Q4 2018 was Wexford Capital, an estimated $1.49M added.
Based on aggregated 13F filings for Q4 2018.